---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000025"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:49:23.315000+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR

## Summary
- 68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.
- Majority of patients showed antigen spreading: T cells targeted additional patient-specific tumor mutations beyond mKRAS.
- Booster doses maintained/increased mKRAS-specific T cell response with increased memory phenotype; no regulatory T cell response detected.
- Preclinical ELI-007 and ELI-008 showed 42-fold to several-hundred-fold increased immune response vs. conventional vaccines.
- Initial clinical data for ELI-002 7P expected in Q2 2024.

## SEC filing metadata
- accession: 0001601485-24-000025
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/0001601485-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/angn-20240405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000025
- JSON: https://secwatch.observer/filing/0001601485-24-000025.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.